BioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
114 SEK | -0.09% | -1.63% | +13.24% |
Apr. 03 | Nordic Shares Rose Wednesday; BW LPG Led Increases | DJ |
Mar. 28 | Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.24% | 1.07B | |
-3.89% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+53.55% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+6.29% | 8.81B |
- Stock Market
- Equities
- BIOG B Stock
- News BioGaia AB
- Biogaia AB Appoints Theresa Agnew as CEO